2026
2026.07 Key challenges in communication across milestones of cancer care continuum: a systematic review. Nguyen VC, Tran K, Phan DT, Pham NT, Shen YA, Chen CL, Huang TW. BMC Palliat Care. 2026 Jul 3;25(1):281. ⏐ Pubmed
2026.06 Fibronectin 1 mediates pressure-induced aggressive phenotypes in colorectal cancer cells and cancer stem cells. Nguyen VC, Cheng KC, Phan TT, Ho TL, Lin YH, Kuo LJ, Shen YA, Chen CL., Cancer Cell Int., 2026 Jun 12;26(1):289. ⏐ Pubmed
2026.06 Critical radiosensitizing parameters of dual-modality gold nanodandelion against cancer radioresistance in MV X-ray and proton therapies. Chuang, Y. C., Chiou, J. F., Wu, P. H., Shen, Y. A., Chang, W. M., Hsia, Y., Kuo, C. C., Wang, W. J., Lo, L. W. & Lee, H. L., Jun 2026, In: Materials Today Advances. 30, 100757.
2026.05 Targeting glutamine metabolism combined with a nanoradioenhancer in radioresistant hepatocellular carcinoma. Kuo CC, Chuang YC, Wu PH, Chang WM, Lo LW, Chen HY, Lee KH, Lee HL, Chiou JF, Shen YA. Nanoscale. 2026 May 14;18(18):9881-9893. doi: 10.1039/d5nr04366b. ⏐ Pubmed
2026.04 Sclerohumins G-L: Selective cytotoxic diterpenoids featuring a 4/9-fused ring system from the soft coral Sclerophytum humesi. Luu, P. V., Phan, T. T. T., Pham, N. T., Le, H. G., Chen, L. Y., Ton-Nu, H. L., Lee, M. H., Shen, Y. A., Fan, Y. J., Chang, Y. C., Su, J. H., Peng, B. R. & Lai, K. H., Apr 2026, In: Phytochemistry. 244, 114756. ⏐ Pubmed
2025
2025.12 High-efficiency engineering of cell membrane nanovesicles with intrinsic homotypic targeting for precision cancer drug delivery. Ho, T. L., Phan, T. T. T., Tsai, I. L., Huynh, T. Q. D., Shen, Y. A. & Fan, Y. J., Dec 2025, International Journal of Biological Macromolecules. 334, 148793.
2025.12 Unusual diterpenoids featuring a 4/9-fused ring system from Sclerophytum humesi trigger intrinsic apoptosis via caspase-dependent PARP cleavage in pancreatic cancer. Luu, P. V., Peng, B. R., Phan, T. T. T., Nguyen, C. Q., Huynh, Q. D. T., Pham, N. T., Le, H. G., Chen, L. Y., Shen, Y. A., Fan, Y. J., & Lai, K. H. Bioorganic Chemistry. 2025 Dec;167:109255. ⏐ Pubmed
2025.10 Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment. Li, T., Akhtarkhavari, S., Qi, S., Fan, J., Chang, T. Y., Shen, Y. A., Yang, J. M., Slusher, B. S., Shih, I. M., Gaillard, S. & Wang, T. L., Oct 2025, Advanced Biology. 9, 10, e00738. ⏐ Pubmed
2025.04 Cytotoxicity-guided isolation of elatostemanosides I-VI from Elatostema tenuicaudatum W. T. Wang and their cytotoxic activities. Huynh, Q. D. T., Phan, T. T. T., Liu, T. W., Duong, T. L. T., Hsu, S. J., Kuo, C. C., Chu, M. H., Wang, Y. H., Nguyen, T. V., Shen, Y. A., Fan, Y. J., Nguyen, D. K., Vo, T. H. & Lee, C. K., Apr 4 2025, In: RSC Advances. 15, 14, p. 10639-10652 14 p. ⏐ Pubmed
2024
2024.11 Association of glutaminase expression with immune-suppressive tumor microenvironment, clinicopathologic features, and clinical outcomes in endometrial cancer. Asaka S, Verma N, Yen TT, Hicks JL, Nonogaki H, Shen YA, Hong J, Asaka R, DeMarzo AM, Wang TL, Shih IM, Gaillard S. Int J Gynecol Cancer. 2024 Nov 4;34(11):1737-1744. (IF: 4.100, OBSTETRICS & GYNECOLOGY, 13/136, 9.6%) ⏐ Pubmed
2024.09 Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies. Chen LY, Wu DS, Shen YA*.
J Lipid Res. 2024 Sep 26;65(11):100660. (IF: 5.000, BIOCHEMISTRY & MOLECULAR BIOLOGY, 64/313, 20.4%) ⏐ Pubmed
2024.06 Active DNA Demethylase, TET1, Increases Oxidative Phosphorylation and Sensitizes Ovarian Cancer Stem Cells to Mitochondrial Complex I Inhibitor. Chen LY, Shen YA, Chu LH, Su PH, Wang HC, Weng YC, Lin SF, Wen KC, Liew PL, Lai HC. Antioxidants. 2024; 13(6):735. (IF: 7.000, CHEMISTRY, MEDICAL, 6/60, 10%)
2024.02 PBX1 as a novel master regulator in cancer: Its regulation, molecular biology, and therapeutic applications. Kao TW, Chen HH, Lin J, Wang TL, Shen YA*. Biochimica et Biophysica Acta (BBA) -Reviews on Cancer 2024, 1879, 2, 189085. (IF: 11.200, BIOPHYSICS, 5/70, 7.1%)
2023
2023.10 Gold Nanodandelions as Nanozymes and Reactive Oxygen Species Scavengers in Tumor Microenvironment Components. Lee HL, Chuang YC, Tsai JT, Chen YC, Wu PH, Lo LW, Chiou JF, Shen YA*. ACS Appl. Nano Mater. 2023, 6, 22, 21359–21370. (IF: 5.900, MATERIALS SCIENCE, MULTIDISCIPLINARY, 97/342, 28.4%)
2023.07 Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy. Yu LY, Shueng PW, Chiu HC, Yen YW, Kuo TY, Li CR, Liu MW, Ho CH, Ho TH, Wang BW, Li CE, Chen MH, Shen YA*, Lo CL*. ACS Nano. 2023 Jul 25;17(14):13158-13175. (IF: 18.027, 5.8%, 20/345, MATERIALS SCIENCE, MULTIDISCIPLINARY)
2023.05 Novel Cancer Treatment Paradigm Targeting HIF in Conjunction with Current Therapies to Overcome Resistance. Kao TW, Bai GH, Wang TL, Shih IM, Chuang CM, Lo CL, Tsai MC, Chiu LY, Lin CC, Shen YA*. J Exp Clin Cancer Res. 2023 Jul 18;42(1):171. (IF: 12.658, 9.8%, 24/245, ONCOLOGY)
2023.03 Frontier Review of the Molecular Mechanisms and Current Approaches of Stem Cell-Derived Exosomes. Chen LY, Kao TW, Chen CC, Niaz N, Lee HL, Chen YH, Kuo CC, Shen YA*. Cells 2023, 12(7), 1018. (IF: 7.666, 26.3%, 51/194, CELL BIOLOGY)
2023.03 Recent Advances in Metal-Based NanoEnhancers for Particle Therapy. Chuang YC, Wu PH, Shen YA, Kuo CC, Wang WJ, Chen YC, Lee HL, Chiou JF. Nanomaterials (Basel). 2023 Mar 10;13(6):1011. (IF: 5.719, 23.0%, 37/161, PHYSICS, APPLIED)
2022
2022.12 Therapeutic Targeting of Glutaminolysis as a Novel Strategy to Combat Cancer Stem Cells. Kao TW, Chuang YC, Lee HL, Kuo CC, Shen YA*. Int J Mol Sci. 2022 Dec 4;23(23):15296. (IF: 6.208, 23.3%, 69/296, BIOCHEMISTRY & MOLECULAR BIOLOGY)
2022.02 Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers. Hong J, Shen YA* (co-corresponding author), Chen CC, Huang P, Tomaszewski A, Gabrielson E, Hsu CY, Shih IM, Gaillard S, Wang TL*. Genes Dis. 2022 Mar 21;9(6):1408-1411. (IF: 7.243, 11.4%, 20/175, GENETICS & HEREDITY)
2022.01 A Few-Shot Learning Approach Assists in the Prognosis Prediction of Magnetic Resonance-Guided Focused Ultrasound for the Local Control of Bone Metastatic Lesions. Hsu FC, Lee HL, Chen YJ, Shen YA, Tsai YC, Wu MH, Kuo CC, Lu LS, Yeh SD, Huang WS, Shen CN, Chiou JF. Cancers (Basel). 2022 Jan 17;14(2):445. (IF: 6.575, 24.5%, 60/245, ONCOLOGY)
2022.01 Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Trasanidis N, Katsarou A, Ponnusamy K, Shen YA, Kostopoulos IV, Bergonia B, Keren K, Reema P, Xiao X, Szydlo RM, Sabbattini P, Roberts I, Auner HW, Naresh KN, Chaidos A, Wang TL, Magnani L, Caputo VS, Karadimitris A. Blood. 2022 Jan 11:blood.2021014391. (IF: 25.476, 2.6%, 2/78, HEMATOLOGY).
2021
2021.11 Enhanced Platelet-Rich Plasma (ePRP) Stimulates Wound Healing through Effects on Metabolic Reprogramming in Fibroblasts. Weng HP, Cheng YY, Lee HL, Hsu TY, Chang YT, Shen YA*. Int. J. Mol. Sci. 2021 Nov 23;22(23):12623. (IF: 6.208, 23.3%, 69/296, BIOCHEMISTRY & MOLECULAR BIOLOGY)
2021.10 Development of Small Molecule Inhibitors Targeting PBX1 Transcription Signaling as a Novel Cancer Therapeutic Strategy. Shen YA, Jung Jin, Shimberg GD, Hsu FC, Rahmanto YS, Gaillard SL, Hong J, Bosch J, Shih IM, Chuang CM, Wang TL. iScience. 2021 Oct 15;24(11):103297. (IF: 6.107, 20.5%, 15/73, MULTIDISCIPLINARY SCIENCES)
2021.07 Potential Therapies Targeting Metabolic Pathways in Cancer Stem Cells. Shen YA, Chen CC, Chen BJ, Wu YT, Juan JR, Chen LY, Teng YC, Wei YH.
Cells. 2021 Jul 13;10(7):1772. (IF: 7.666, 26.3%, 51/194, CELL BIOLOGY)
2021.06 Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment. Shen YA, Chen CL, Huang YH, Evans EE, Cheng CC, Chuang YJ, Zhang C, Le A. Curr Opin Chem Biol. 2021 Jun;62:64-81. (IF: 8.972, 8.3%, 6/72, BIOPHYSICS)
2020
2020.08 Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers. Shen YA, Hong JX, Asaka R, Asaka S, Hsu FC, Rahmanto YS, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL. Cancer Res. 2020 Oct 15;80(20):4514-4526. (IF: 13.312, 8.2%, 20/245, ONCOLOGY)
2020.02 Targeting Cancer Stem Cells from a Metabolic Perspective. Shen YA, Pan SC, Chu I, Lai RY, Wei YH. Exp Biol Med (Maywood). 2020 Mar;245(5):465-476. (IF: 4.088, 54.7%, 76/139, MEDICINE, RESEARCH & EXPERIMENTAL)
2019
2019.09 Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. Yu Y, Rahmanto YS, Shen YA, Ardighieri L, Davidson B, Gaillard S, Ayhan A, Shi X, Xuan J, Wang TL, Shih IM. EBioMedicine. 2019 Sep;47:184-194. (IF: 11.205, 10.1%, 14/139, MEDICINE, RESEARCH & EXPERIMENTAL)
2019.04 Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, Antonio MJ, Camelo F, Li T, Nguyen S, Hoang G, Nguyen K, Udupa S, Sazeides C, Shen YA, Elgogary A, Reyes J, Zhao L, Kleensang A, Chaichana KL, Hartung T, Betenbaugh MJ, Marie SK, Jung JG, Wang TL, Gabrielson E, Le A. Cell Rep. 2019 Apr 9;27(2):491-501.e6. (IF: 9.995, 17.0%, 33/194, CELL BIOLOGY)
2019.04 The feasibility of ROS- and GSH-responsive micelles for treating tumor-initiating and metastatic cancer stem cells. Yu LY, Shen YA, Chen MH, Wen YH, Hsieh PI, Lo CL. J. Mater. Chem. B, 2019,7, 3109-3118. (IF: 7.571, 22.7%, 10/44, MATERIALS SCIENCE, BIOMATERIALS)
2018-2012
2018.09 pH- and GSH-sensitive hyaluronic acid-mp conjugate micelles for intracellular delivery of doxorubicin to colon cancer cells and cancer stem cells. Debele TA, Yu LY, Yang CS, Shen YA, Lo CL. Biomacromolecules. 2018 Sep 10;19(9):3725-3737. (IF: 6.978, 5.4%, 3/56, CHEMISTRY, ORGANIC)
2017.08 A pH sensitive polymeric micelle for co-delivery of doxorubicin and a-TOS for colon cancer therapy.Debele TA, Lee KY, Hsu NY, Chiang YT, Yu LY, Shen YA, Lo CL. J. Mater. Chem. B, 2017, 5, 5870-5880. (IF: 7.571, 22.7%, 10/44, MATERIALS SCIENCE, BIOMATERIALS)
2017.06 CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation. Shen YA, Wang CY, Chuang HY, Hwang JJ, Chi WH, Shu CH, Ho CY, Li WY, Chen YJ. Oncotarget. 2016 Sep 6;7(36):58351-58366.
2016.02 Intraperitoneal 188Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice. Shen YA, Lan KL, Chang CH, Lin LT, He CL, Cheng PH, Lee TW, Lee YJ, Chuang CM* Radiother Oncol. 2016 Feb 22. pii: S0167-8140(16)00065-7. (IF: 6.901, 16.2%, 22/136, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING)
2015.05 Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol® -resistant ovarian cancer. Shen YA, Li WH, Chen PH, He CL, Chang YH, Chuang CM. Am J Transl Res. 2015 May 15;7(5):841-55. eCollection 2015. (IF: 3.940, 55.9%, 137/245, ONCOLOGY)
2015.04 Subtype-specific binding peptides enhance the therapeutic efficacy of nanomedicine in the treatment of ovarian cancer. Shen YA, Liu CS, Chang YH, Chen PH, He CL, Wu HC, Chuang CM. Cancer Lett. 2015; 360(1):39-47. (IF: 9.756, 14.3%, 35/245, ONCOLOGY )
2015.01 Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control. Shen YA, Lu M, Shyu IL, Hsu YM, Liang HF, Liu CP, Wei MC, Tsai YJ, Wei YH*, Chuang CM* Int J Nanomed. 2015; 30;10:2485-502. (IF: 7.033, 11.1%, 31/279, PHARMACOLOGY & PHARMACY)
2014.10 Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma. Shen YA, Wang CY, Hsieh YT, Chen YJ*, Wei YH*. Cell Cycle 2015;14(1):86-98. (IF: 5.173, 45.9%, 89/194, CELL BIOLOGY)
2013.03 Resveratrol impedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Shen YA, Lin CH, Chi WH, Wang CY, Hsieh YT, Wei YH*, Chen YJ*. Evid Based Complement Alternat Med. 2013;2013:590393. (IF: 2.650, 53.3%, 16/30, INTEGRATIVE & COMPLEMENTARY MEDICINE)
2012.03 Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines. Lin CH, Shen YA, Hung PH, Yu YB, Chen YJ*. BMC Complement Altern Med. 2012;12:201. (IF: 4.782, 16.7%, 5/30, INTEGRATIVE & COMPLEMENTARY MEDICINE)
2012.09 High mitochondrial DNA copy number and bioenergetic function are associated with tumor invasion of esophageal squamous cell carcinoma cell lines. Lin CS, Lee HT, Lee SY, Shen YA, Wang LS, Chen YJ, Wei YH*. Int J Mol Sci. 2012;13(9):11228-46. (IF: 6.208, BIOCHEMISTRY & MOLECULAR BIOLOGY, 69/296, 23.3%)